PeptiDream Announces Discovery Collaboration Agreement with Bayer

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG (“Bayer”)(ETR:BAYN). Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple targets of interest selected by Bayer, and to optimize hit peptides into therapeutic peptides or small molecule products. Bayer also holds an exercisable option to negotiate for an extension of the license to peptide-drug conjugate (PDC), diagnostic, bioimaging, and agricultural use and applications. Bayer will have the right to develop and commercialize all compounds resulting from the collaboration. Under the terms of the agreement, PeptiDream would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (¥124.5 billion). In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.

[Comment from Patrick Reid, CEO of PeptiDream Inc] “We are extremely excited to be initiating this discovery alliance with Bayer. This is one of the broadest discovery deals PeptiDream has entered into, covering peptide therapeutics and small molecule therapeutics, and options to peptide drug conjugates (PDCs), diagnostic agents, bioimaging agents, and more. This deal further exemplifies the power of our PDPS platform and the impact it is having on early drug discovery. We greatly look forward to working with Bayer to leverage both companies’ expertise and capabilities to discover and development the next generation of first-in-class and best-in-class therapeutics.”

In the past seven years, PeptiDream has established funded discovery collaborations with 17 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, and Janssen, all of which are active and ongoing. November 16 th , 2017 PeptiDream Inc. h t t p : / / w w w . p e p t i d ream . c om / (Ticker Code:4587 TSE First Section) In addition, PeptiDream has transferred its PDPS discovery platform for broad use to BristolMyers-Squibb, Novartis, Lilly, Genentech, and Shionogi.

About PeptiDream Inc.
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit

0 Comments Write your comment

    1. Loading...